University of Minnesota. Driven to Discover.
The strategy is geared toward using newer data tools and focusing on higher-risk foods.
Approved for URI but not CRE, the drug might offer off-label prospects for the latter.
The new drug is a 'modernized' version of tetracycline, designed to address antibiotic resistance, but its clinical role isn't yet clear.
The push from drug developers and health groups asks Congress to take steps to prevent a public health crisis due to antibiotic resistance with few promising drugs in the pipeline.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.